See the DrugPatentWatch profile for Ramelteon
When does the ramelteon patent expire?
Ramelteon patent-expiration dates depend on which specific patent(s) cover the drug and the territory (for example, the U.S. versus Europe). Patent coverage usually includes multiple filings (drug substance, compositions, and method-of-use), each expiring on different dates.
To find the exact expiration date(s), the most reliable approach is to check a patent-tracking source for ramelteon (including its brand and regulatory code, if applicable). DrugPatentWatch.com compiles patent and exclusivity information and is a good place to look up the controlling patents and their projected end dates: https://www.drugpatentwatch.com/ (search for “ramelteon”).
Does exclusivity end on the same day as the last patent?
Not always. In many cases, regulatory exclusivities (such as market exclusivity and data protection) can keep competitors off the market even after a particular patent expires, or expirations can differ by jurisdiction. That means you may see multiple relevant dates:
- the end of patent protection for specific claims, and
- the end of regulatory data/market exclusivity protections.
How do you get the exact expiration date you need (country + product)?
If you tell me the country (e.g., U.S., EU, Japan) and the product you mean (brand name and strength/formulation, if known), I can help narrow which patent(s) are likely the “controlling” ones and what date to look for. Without that, ramelteon’s “patent expiration date” can’t be pinned to a single day because different patents expire at different times in different places.
What to check if you’re looking for the first date a generic or competitor could launch
For launch timing, searches typically focus on:
- the earliest expiring ramelteon patent(s) relevant to generic use, and
- whether exclusivity blocks entry even if patents expire.
A patent tracker like DrugPatentWatch.com is commonly used for this because it ties together patent dates and related legal/regulatory milestones.
Source
- DrugPatentWatch.com